小分子KRAS抑制剂通过铁共价键形成
Alexander Landgraf1, Robert Brenner1, Mona Ghozayel2
1Indiana University School of Medicine, Biochemistry, UNITED STATES OF AMERICA.
ChemMedChem
|March 18, 2025
概括
研究人员发现了一种新的向氨酸残留的KRAS抑制剂,提供了一种超越KRAS G12C突变的新策略. 这种方法扩大了对KRAS驱动的癌症的共价药物开发.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 克拉斯突变驱动许多癌症,但像索托拉西布 (克拉斯G12C抑制剂) 这样的向疗法只针对一个子集.
- 克拉斯蛋白具有氨酸残留物,为共价药物开发提供潜在的替代部位.
研究的目的:
- 为了确定针对KRAS的新型共价抑制剂.
- 探索氨酸残留物作为KRAS抑制的潜在核友.
- 开发针对超出G12C突变的KRAS驱动瘤的新策略.
主要方法:
- 选亚利硫尼尔化物以确定KRAS抑制剂.
- 利用质谱学,核酸交换试验,效应体结合试验和NMR来描述抑制剂结合.
- 采用共晶结构和NanoBRET测试来验证目标参与和细胞活动.
主要成果:
- 亚利硫尼尔化物SOF-436被确定为KRAS抑制剂,主要针对Tyr-64和Tyr-71.
- SOF-436抑制了KRAS核酸交换和与SOS1和RAF的结合.
- 晶结构揭示了碎片与Switch II口袋的结合,为Switch I/II抑制剂设计提供了基础.
结论:
- 在KRAS上的氨酸残留物可以作为对共价抑制的有效标.
- 这些发现为KRAS驱动的癌症提供了新的治疗策略,扩大了治疗选择.
- 已识别的碎片是开发新型小分子KRAS抑制剂的起点.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.5K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
相关概念视频
Receptor Tyrosine Kinases
12.0K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.0K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
The Ras Gene
6.1K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.1K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
